<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981851</url>
  </required_header>
  <id_info>
    <org_study_id>RvB08.066.51196/GE</org_study_id>
    <nct_id>NCT00981851</nct_id>
  </id_info>
  <brief_title>Interaction in Chronic Obstructive Pulmonary Disease Experiment</brief_title>
  <acronym>ICE</acronym>
  <official_title>A Hazardous Combination of Cigarette Smoking and Bronchodilation in Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The final purpose of this study is to determine whether bronchodilation and cigarette smoking&#xD;
      in Chronic Obstructive Pulmonary Disease (COPD) patients interact, resulting in an increase&#xD;
      of cardiovascular disease. The aim of this part of the study is to demonstrate the basic&#xD;
      mechanism: Does increased respiratory function after administration of a bronchodilator in&#xD;
      patients with COPD lead to elevated pulmonary retention of the harmful compounds in inhaled&#xD;
      cigarette smoke and to short-term biological effects associated with cardiovascular disease?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COPD currently is one of the most frequent diseases. In more than 80% of COPD patients, the&#xD;
      disease is caused by smoking. About half of the COPD patients are active smokers, although&#xD;
      smoking is also the most important prognostic factor. Also, smoking is an important cause as&#xD;
      well as an important prognostic factor in cardiovascular disease. The corner stone of medical&#xD;
      treatment in COPD is bronchodilation; more than half of the patients use a long-acting&#xD;
      bronchodilator. An increase of the pathogenic effect of smoking by an increased lung function&#xD;
      after bronchodilation is likely though, since more pathogenic particles would penetrate the&#xD;
      lung. We hypothesize that bronchodilators increase cardiovascular disease in COPD patients&#xD;
      who smoke.&#xD;
&#xD;
      In order to demonstrate the basic mechanism of our hypothesis, COPD patients receive a&#xD;
      bronchodilator at one time and a placebo at another time, preceded and followed by cigarette&#xD;
      smoking during one hour as by a strict time schedule. Smoke retention, lung function and&#xD;
      blood biomarkers are repeatedly measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cigarette smoke retention</measure>
    <time_frame>retention measurement is during smoking. smoking is 1 cigarette before and 1 cigarette 45 minutes after medication inhalation for each arm. 1 week between arms</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(hs)CRP</measure>
    <time_frame>3 times within 2 hours for each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrinogen</measure>
    <time_frame>3 times within 2 hours for each arm</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory function</measure>
    <time_frame>at baseline and repeatedly around medication inhalation for 1.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>smoking pattern: smoke inhalation and smoke exhalation time and volume</measure>
    <time_frame>during smoking cigarettes: twice for each arm.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Smoking</condition>
  <condition>Bronchodilation</condition>
  <arm_group>
    <arm_group_label>beta 2 agonist + anticholinergic aerosol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo inhalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium (Spiriva) + Salbutamol (Ventolin)</intervention_name>
    <description>1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking</description>
    <arm_group_label>beta 2 agonist + anticholinergic aerosol</arm_group_label>
    <other_name>Spiriva Respimat</other_name>
    <other_name>Ventolin Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking</description>
    <arm_group_label>placebo inhalation</arm_group_label>
    <other_name>Ventolin placebo and Spiriva placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD Gold stage II-III (FEV1/FVC&lt;0,70 and FEV1 30-80% of predicted value).&#xD;
&#xD;
          -  Current cigarette smoking (at the time of performing the study).&#xD;
&#xD;
          -  Willing to provide written informed consent.&#xD;
&#xD;
          -  Refrain from smoking and bronchodilators &gt; 8 hours (depends on treatment) before the&#xD;
             test.&#xD;
&#xD;
          -  Registered in one of the recruitment institutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COPD gold stage I or IV.&#xD;
&#xD;
          -  Asthmatic component: History of asthma, present asthma by complaints, eosinophilia or&#xD;
             reversibility ≥ 10% of predicted.&#xD;
&#xD;
          -  Unable to communicate.&#xD;
&#xD;
          -  Physically unable to perform any of the tests.&#xD;
&#xD;
          -  Non-COPD respiratory disorders.&#xD;
&#xD;
          -  Previous lung-volume reduction surgery and/or lung transplantation.&#xD;
&#xD;
          -  Evidence of alcohol, drug or solvent abuse.&#xD;
&#xD;
          -  Known α-1 antitrypsin deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tjard RJ Schermer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Center for Chronic Diseases Dekkerswald</name>
      <address>
        <city>Groesbeek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary care, general practitioners</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>September 21, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <last_update_submitted>July 4, 2011</last_update_submitted>
  <last_update_submitted_qc>July 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>TRJ Schermer, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Center</organization>
  </responsible_party>
  <keyword>intervention study</keyword>
  <keyword>interaction</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

